IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | Other Management Information(Voluntary Disclosure)(국책과제 선정(HPV16 및/또는 HPV18 양성인, 절제 불가능한 재발성 또는 전이성 두경부편평상피세포암 치료제 BVAC-E6E7의 임상 1상 개발)) | 2025-11-18 | |
| 9 | Lawsuit (Charging More Than Certain Amount) | 2025-09-18 | |
| 8 | Settlement of Lawsuit (Charging More Than Certain Amount) | 2025-08-12 | |
| 7 | Additional Listing(유상증자(구주주배정)) | KOSDAQ STOCK MKT. | 2025-07-02 |
| 6 | Results of issuance(Voluntary Disclosure) | 2025-06-24 | |
| 5 | Results of Subscription (Voluntary Disclosure) | 2025-06-23 | |
| 4 | Results of Subscription (Voluntary Disclosure) | 2025-06-18 | |
| 3 | Extension of overheated short-selling issue designation (subject to extension of restriction on short-selling) | KOSDAQ STOCK MKT. | 2025-06-13 |
| 2 | Release from designation as Investment Alert Issue & Prior notice on Re-designation | 2025-06-12 | |
| 1 | Designation of overheated short-selling issues (applied by a restriction on short-selling) | KOSDAQ STOCK MKT. | 2025-06-12 |
